AstraZeneca's immunotherapy drug wins key lung cancer approval

LONDON (Reuters) – AstraZeneca’s immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *